3期临床-话题@MedSci

#3期临床#

90篇内容 | 1367人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1911270, encodeId=107b19112e0ef, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=27, createdTime=2021-10-29, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911280, encodeId=638c1911280a2, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=31, createdTime=2021-11-13, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911281, encodeId=c49c1911281aa, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Nature Medicine: 新晋院士徐兵河论文：治疗耐药性晚期乳腺癌的3期临床试验, objectType=article, longId=220854, objectId=1e7b22085476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7b22085476, replyNumber=0, likeNumber=39, createdTime=2022-01-25, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7b22085476, moduleTitle=Nature Medicine: 新晋院士徐兵河论文：治疗耐药性晚期乳腺癌的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e7b22085476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911265, encodeId=0dbd19112654f, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=阿斯利康公布新冠疫苗3期临床试验安全性和有效性, objectType=article, longId=209051, objectId=e07a20905132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e07a20905132, replyNumber=0, likeNumber=36, createdTime=2021-10-15, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e07a20905132, moduleTitle=阿斯利康公布新冠疫苗3期临床试验安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e07a20905132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911264, encodeId=94801911264f3, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=NEJM：ALVAC-HIV疫苗接种方案在南非2b-3期临床研究失败, objectType=article, longId=209012, objectId=404d20901249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=404d20901249, replyNumber=0, likeNumber=42, createdTime=2021-04-28, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=404d20901249, moduleTitle=NEJM：ALVAC-HIV疫苗接种方案在南非2b-3期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=404d20901249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911271, encodeId=6c1819112e129, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Burns：“人造皮肤”3期临床结果发布，让创伤愈合不留疤痕, objectType=article, longId=214012, objectId=8dac214012c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dac214012c4, replyNumber=0, likeNumber=32, createdTime=2021-07-15, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dac214012c4, moduleTitle=Burns：“人造皮肤”3期临床结果发布，让创伤愈合不留疤痕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dac214012c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911267, encodeId=1080191126e85, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, objectType=article, longId=210730, objectId=22a4210e30f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a4210e30f6, replyNumber=0, likeNumber=34, createdTime=2021-07-04, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a4210e30f6, moduleTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22a4210e30f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911282, encodeId=aee21911282b1, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, objectType=article, longId=221546, objectId=86b522154637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b522154637, replyNumber=0, likeNumber=36, createdTime=2021-12-10, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b522154637, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b522154637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911276, encodeId=ec7219112e6f7, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, objectType=article, longId=215469, objectId=aafc2154691d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc2154691d, replyNumber=0, likeNumber=45, createdTime=2021-09-22, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc2154691d, moduleTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafc2154691d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911277, encodeId=0c0119112e7f2, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=长效预防新冠抗体组合药物3期临床效果积极，显著有降低有症状发病率, objectType=article, longId=216479, objectId=5a832164e9c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a832164e9c1, replyNumber=0, likeNumber=37, createdTime=2022-08-02, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a832164e9c1, moduleTitle=长效预防新冠抗体组合药物3期临床效果积极，显著有降低有症状发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a832164e9c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911278, encodeId=225a19112e88c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JAMA：卡瑞丽珠单抗联合化疗一线治疗明显改善晚期食管鳞状细胞癌患者的预后：3期临床研究ESCORT-1st, objectType=article, longId=217175, objectId=e7b321e1759e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7b321e1759e, replyNumber=0, likeNumber=53, createdTime=2021-10-24, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7b321e1759e, moduleTitle=JAMA：卡瑞丽珠单抗联合化疗一线治疗明显改善晚期食管鳞状细胞癌患者的预后：3期临床研究ESCORT-1st, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7b321e1759e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911275, encodeId=60fa19112e5eb, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究, objectType=article, longId=215448, objectId=f2db21544877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2db21544877, replyNumber=0, likeNumber=34, createdTime=2022-07-03, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2db21544877, moduleTitle=Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2db21544877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911266, encodeId=09c819112668c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, objectType=article, longId=209670, objectId=f8062096e0cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8062096e0cf, replyNumber=0, likeNumber=34, createdTime=2021-05-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8062096e0cf, moduleTitle=Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8062096e0cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911279, encodeId=3fc919112e92f, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极, objectType=article, longId=217282, objectId=829521e282c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829521e282c1, replyNumber=0, likeNumber=31, createdTime=2022-02-15, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829521e282c1, moduleTitle=显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829521e282c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911269, encodeId=11e11911269fa, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合吉西他滨+铂类一线治疗局部进展或转移性鳞状非小细胞肺癌的疗效和安全性：随机双盲3期临床研究（ORIENT-12）。, objectType=article, longId=211989, objectId=b7c021198974, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7c021198974, replyNumber=0, likeNumber=42, createdTime=2021-10-27, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7c021198974, moduleTitle=JTO:信迪利单抗（Sintilimab）联合吉西他滨+铂类一线治疗局部进展或转移性鳞状非小细胞肺癌的疗效和安全性：随机双盲3期临床研究（ORIENT-12）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7c021198974)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911261, encodeId=c83d19112614d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=中国阿尔茨海默病新药在美启动国际3期临床试验, objectType=article, longId=203104, objectId=8081203104cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8081203104cf, replyNumber=0, likeNumber=39, createdTime=2021-10-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8081203104cf, moduleTitle=中国阿尔茨海默病新药在美启动国际3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8081203104cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911268, encodeId=b7b619112685a, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, objectType=article, longId=211375, objectId=15302113e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15302113e548, replyNumber=0, likeNumber=50, createdTime=2021-09-04, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15302113e548, moduleTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15302113e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911263, encodeId=93bc191126396, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究, objectType=article, longId=207233, objectId=008b20e23326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=008b20e23326, replyNumber=0, likeNumber=38, createdTime=2021-11-26, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=008b20e23326, moduleTitle=基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=008b20e23326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911272, encodeId=85b519112e2dd, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Liver Cancer：不可切除肝细胞癌患者基线肝功能和预后的关系：来自3期临床研究REFLECT患者的分析结果, objectType=article, longId=214329, objectId=ec54214329a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec54214329a3, replyNumber=0, likeNumber=32, createdTime=2022-06-24, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec54214329a3, moduleTitle=Liver Cancer：不可切除肝细胞癌患者基线肝功能和预后的关系：来自3期临床研究REFLECT患者的分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec54214329a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911255, encodeId=a1a31911255b9, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle= Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果, objectType=article, longId=200216, objectId=67e12002166e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e12002166e, replyNumber=0, likeNumber=41, createdTime=2021-06-15, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e12002166e, moduleTitle= Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e12002166e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期临床

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2021-10-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2021-11-13

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Nature Medicine: 新晋院士徐兵河论文：治疗耐药性晚期乳腺癌的3期临床试验

2022-01-25

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

阿斯利康公布新冠疫苗3期临床试验安全性和有效性

2021-10-15

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

NEJM：ALVAC-HIV疫苗接种方案在南非2b-3期临床研究失败

2021-04-28

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Burns：“人造皮肤”3期临床结果发布，让创伤愈合不留疤痕

2021-07-15

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果

2021-07-04

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL

2021-12-10

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。

2021-09-22

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

长效预防新冠抗体组合药物3期临床效果积极，显著有降低有症状发病率

2022-08-02

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JAMA：卡瑞丽珠单抗联合化疗一线治疗明显改善晚期食管鳞状细胞癌患者的预后：3期临床研究ESCORT-1st

2021-10-24

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Nat Med：Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究

2022-07-03

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Lancet Neurology：onasmonogene abeparvovec治疗有症状的婴儿型脊髓性肌萎缩症患者的3期临床试验

2021-05-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

显著减轻疼痛并改善功能骨关节炎创新疗法3期临床结果积极

2022-02-15

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JTO:信迪利单抗（Sintilimab）联合吉西他滨+铂类一线治疗局部进展或转移性鳞状非小细胞肺癌的疗效和安全性：随机双盲3期临床研究（ORIENT-12）。

2021-10-27

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

中国阿尔茨海默病新药在美启动国际3期临床试验

2021-10-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

2021-09-04

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

基因治疗出岔子了？蓝鸟(Bluebird Bio)暂停LentiGlobin基因疗法1/2、3期临床研究

2021-11-26

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Liver Cancer：不可切除肝细胞癌患者基线肝功能和预后的关系：来自3期临床研究REFLECT患者的分析结果

2022-06-24

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Lancet respirat med：托珠单抗治疗系统性硬化症的3期临床试验结果

2021-06-15

科室
- - 订阅+
  - 更多科室
工具
服务